araag2/HINT huggingface dataset:
Clinical trial NCT00473525 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, pf-00734200 10 mg qd, pf-00734200 20 mg qd, pf-00734200 5 mg qd, pf-00734200 2 mg qd
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1, [H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCC(F)(F)C1)N1CCN(CC1)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Hb1AC >7%-11% inclusive

          -  Male and females 18-70; females must be post-menopausal

          -  On a stable dose of metformin hydrochloride

        Exclusion Criteria:

          -  Medical history of stroke, unstable angina, heart attack within one year of
             enrollment, and alcohol dependency or recent drug abuse.

          -  Women of childbearing potential, pregnant or nursing

          -  Evidence of diabetic complications with significant end-organ damage
Clinical trial NCT00440154 (phase 2, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ave5530, placebo, ezetimibe
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mild to moderate primary hypercholesterolemia with stabilized LDL-C
             baseline ≥130 mg/dL and ≤ 250 mg/dL (≥ 3.36 mmol/L and ≤ 6.46 mmol/L)

          -  Male aged ≥ 18 years or postmenopausal women at screening

        Exclusion Criteria:

          -  Presence of any clinically significant endocrine disease known to influence serum
             lipids or lipoproteins

          -  Patients with type 1 diabetes

          -  Presence or history of cancer within the past five years

          -  Triglycerides ≥ 300 mg/dL (3.39 mmol/L)

          -  Fasting plasma glucose > 160 mg/dL (8.9 mmol/L)

          -  Impaired kidney function and active liver disease

          -  Within one month prior to screening visit and/or at the time or after the screening
             visit, administration of any lipid lowering treatment

          -  Creatine Kinase > 2xUpper Limit of Normal range

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00413023 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: gw679769
SMILES: C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion criteria:

          -  Primary diagnosis of Major depressive Disorder as defined in DSM-IV.

          -  Capable of giving informed consent and willing to comply with the study requirements.

          -  Women of childbearing potential must agree to one of a number of defined acceptable
             methods of birth control.

        Exclusion Criteria:

          -  Primary diagnosis within the past 6 months of another Axis 1 disorder such as an
             anxiety disorder.

          -  Use of medications for a psychiatric condition including herbals in the past 2-12
             weeks according to medication type.

          -  Subjects who, in the investigator's judgement, pose a current, serious suicidal or
             homicidal risk or have made a suicide attempt within the past 6 months.

          -  Subjects who currently meet or who met within 6 months prior to screening DSM-IV
             criteria for substance abuse or subjects who currently meet or who met within 6 months
             prior to screening DSM-IV criteria for substance dependence (other than nicotine).

          -  Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).
Clinical trial NCT00367887 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: peg-intron, rebetol, hcv 796, peg-intron, rebetol, hcv 796, peg-intron, rebetol
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=C(OC2=CC(N(CCO)S(C)(=O)=O)=C(C=C12)C1CC1)C1=CC=C(F)C=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=C(OC2=CC(N(CCO)S(C)(=O)=O)=C(C=C12)C1CC1)C1=CC=C(F)C=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection with HCV genotype 1.

          -  HCV- infected subjects naive to treatment.

          -  HCV-infected non-responder subjects.

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding.

          -  ALT >/ or = 5X the upper limit of normal.

          -  AST >/ or = 5X the upper limit of normal.
Clinical trial NCT00619164 (phase 2, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: e5555, e5555, e5555, placebo
SMILES: CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. 45 - 80 years old (at time of informed consent)

          2. Male or female (females of childbearing potential must be contracepted)

          3. Confirmed acute coronary syndrome

        Exclusion Criteria:

          1. Unwilling or unable to provide informed consent

          2. History of acquired or congenital bleeding disorder, coagulopathy, or platelet
             disorder

          3. Recent trauma or major surgery

          4. Evidence of active pathological bleeding at screening or history of gastrointestinal
             or genitourinary bleeding with unknown cause within 24 weeks prior to screening

          5. History of intracranial bleeding or history of hemorrhagic retinopathy

          6. History of New York Heart Association (NYHA) class III or IV congestive heart failure

          7. Pregnant or lactating women
Clinical trial NCT01090492 (phase 2, status: completed)
Conditions: raynaud's disease, peripheral vascular disease
ICD codes: I73.00, I73.01, I73.9, I73.89
Drugs: pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791, pf-00489791
SMILES: CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC, CCOCCN1N=C(C(=O)NS(C)(=O)=O)C2=NC(=NC(NC3=CC(C)=CC=N3)=C12)N(C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  Active Raynaud's Phenomenon

          -  Stable disease and medication requirements over the previous two months

          -  For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the
             American College of Rheumatology criteria or by the presence of at least 3/5 features
             of CREST syndrome

          -  both sexes

        Exclusion Criteria:

          -  Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates

          -  Smoking within 3 months or smoking cessation using nicotine products

          -  Subjects currently taking sildenafil, tadalafil or vardenafil

          -  Subjects with ulnar arterial occlusive disease as shown by a modified Allen test

          -  Pregnant or breast feeding or considering pregnancy in next 4 months

          -  Participation in trial for investigational drug within 30 days
Clinical trial NCT01401673 (phase 2, status: terminated)
Conditions: cough
ICD codes: R05.1, R05.2, R05.3, R05.4, R05.9, G44.83, J45.991
Drugs: indantadol
SMILES: NC(=O)CNC1CC2=CC=CC=C2C1
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female 18-75 years of age

          -  Females must be of non child-bearing potential

          -  Chronic Cough ( > 8 weeks)

          -  Normal Chest X-ray

          -  Normal Lung Function

          -  Idiopathic or treatment resistant cough-

        Exclusion Criteria:

          -  Recent upper respiratory tract infection (<4 weeks)

          -  Pregnancy/breast-feeding

          -  Current smokers or ex-smokers with <6 months abstinence or cumulative history of >10
             pack years

          -  Current treatment with ACE inhibitors.

          -  Drug or alcohol abuse

          -  Uncontrolled hypertension (i.e., >140/90 mmHg despite adequate medical therapy).

          -  Any cardiovascular condition that would be a contra-indication to the use of
             sympathomimetic amines (e.g. active angina).

          -  Any clinically significant neurological disorder

          -  Prior renal transplant, current renal dialysis.

          -  Any clinically significant or unstable medical or psychiatric condition that would
             interfere with the patient's ability to participate in the study.

          -  Increased risk of seizures.

          -  Any malignancy in the past 2 years (with the exception of basal cell carcinoma).

          -  Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).

          -  Any clinically significant abnormal laboratory test result(s).

          -  Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN)
             reference range (after adjustment for age) or estimated creatinine clearance <60
             mL/min.

          -  Total bilirubin greater than upper limit of normal reference range (with the exception
             of Gilbert's Syndrome) and/or alanine transaminase (ALT) >1.5 times upper limit of
             normal reference ranges (after adjustment for age).
Clinical trial NCT00261846 (phase 2, status: completed)
Conditions: chronic myeloid leukemia
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: bosutinib
SMILES: COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Ph+ CML or Ph+ ALL who are primarily refractory to full-dose imatinib (600 mg), have
             disease progression/relapse while on full-dose imatinib, or are intolerant of any dose
             of imatinib.

          -  At least 3 months post stem cell transplantation

          -  Able to take daily oral capsules/tablets reliably

        Exclusion Criteria:

          -  Subjects with Philadelphia chromosome, and bcr-abl negative CML

          -  Overt leptomeningeal leukemia

          -  Subjects without evidence of leukemia in bone marrow (extramedullary disease only)
Clinical trial NCT00840450 (phase 2, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gleevec/paclitaxel
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients at least 18 years of age.

          -  Histologically documented diagnosis of epithelial carcinoma arising in the ovary,
             fallopian tube or peritoneum, of any stage or grade at diagnosis. *Patients must have
             received initial cytoreductive surgery and chemotherapy with at least one platinum
             based chemotherapy regimen.

             *Eligible platinum resistant patients will have failed no more than two additional non
             platinum cytotoxic regimens for their persistent or recurrent disease.

          -  Measurable disease.

          -  Performance status 0, 1, 2 (Eastern Cooperative Oncology Group) .

          -  Adequate end organ function, defined as the following: total bilirubin < 1.5 x upper
             limit of normal (ULN), SGOT and SGPT < 2.5 x UNL, creatinine < 1.5 x ULN, ANC > 1.0 x
             10E9/L, platelets > 100 x 10E9/L.

          -  Written, voluntary informed consent.

        Exclusion Criteria:

          -  Patient has received any other anticancer treatment within 21 days of first day of
             study drug dosing and shown recovery of any recent drug-induced neutropenia and
             thrombocytopenia.

          -  Patient has another primary malignancy that has required active intervention within 5
             years, with the exception of basal cell skin cancer or a cervical carcinoma in situ.

          -  Patient with Grade III/IV cardiac problems as defined by the New York Heart
             Association Criteria (i.e., congestive heart failure, myocardial infarction within 6
             months of study).

          -  Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes,
             chronic renal disease, or active uncontrolled infection).

          -  Patients on coumadin-derived anticoagulants.

          -  Patient with brain metastasis.

          -  Chronic liver disease, Hep B or C.

          -  Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

          -  Patient received chemotherapy within 3 weeks -unless the disease is rapidly
             progressing.

          -  Patient previously received radiotherapy to at least 25 % of the bone marrow.

          -  Patient had a major surgery within 2 weeks prior to study entry.

          -  Patient with any significant history of non-compliance to medical regimens or with
             inability to grant reliable informed consent.

          -  Patient is on any drug that may interfere with Gleevec (e.g., Dilantin, Coumadin,or
             others on the list on page 33-37 of the protocol).
Clinical trial NCT00648167 (phase 2, status: completed)
Conditions: hyperphosphatemia, end-stage renal disease
ICD codes: N18.6, I12.0, I13.11, I13.2
Drugs: ferric citrate
SMILES: [Fe+3]
Eligibility criteria:

        Inclusion Criteria:

          -  Males and non-pregnant, nonlactating females

          -  Age > 18 years

          -  On thrice weekly hemodialysis for at least the previous 3 months prior to
             randomization

          -  Phosphorous levels ≥3.5mg/dL at Screening Visit

          -  On at least 12 tablets/capsules/day of calcium acetate (667mg), calcium carbonate
             (500mg), lanthanum carbonate (500mg), sevelamer hydrochloride (800mg or two 400mg
             tablets), or any combination of these agents

          -  Serum ferritin <1000micrograms/L and Transferrin Saturation (TSAT) <50%

          -  Willing to be discontinued from current phosphate binder(s) and initiated on Zerenex

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Parathyroidectomy within 6 months prior to Screening

          -  Actively symptomatic GI disease such as peptic ulcer disease, gastro esophageal
             reflux, diverticulosis, irritable bowel syndrome (treated asymptomatic is permitted)

          -  History of documented inflammatory bowel disease or erosive esophagitis

          -  Serum Phosphorus levels >10.0 mg/dL documented in the 3 monthly laboratories (done
             routinely in the dialysis unit) in the 3 months prior to the Screening Visit

          -  History of multiple drug allergies

          -  History of malignancy in the last 5 years (treated cervical or skin cancer may be
             permitted if approved by CCC)

          -  Previous intolerance to oral ferric citrate

          -  Absolute requirement for oral iron therapy

          -  Absolute requirement for Vitamin C (multivitamins [Neprocaps, Renaphro, etc.] allowed)

          -  Absolute requirement for calcium, magnesium, or aluminum containing drugs with meals

          -  Psychiatric disorder that interferes with the patient's ability to comply with the
             study protocol

          -  Inability to tolerate oral drug intake

          -  Planned surgery or hospitalization during the study (scheduled outpatient access
             surgery allowed)

          -  Any other medical condition that renders the patient unable to or unlikely to complete
             the study or that would interfere with optimal participation in the study or produce
             significant risk to the patient

          -  Receipt of any investigational drug within 30 days of randomization

          -  Inability to cooperate with study personnel or history of noncompliance
Clinical trial NCT00359164 (phase 2, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: verteporfin photodynamic therapy (low fluence) and bevacizumab, verteporfin photodynamic therapy (very low fluence) and bevacizumab, verteporfin photodynamic therapy (sham) and bevacizumab
SMILES: COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C, COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C
Eligibility criteria:

        Inclusion Criteria:

        new wet AMD

        Exclusion Criteria:

        -
Clinical trial NCT00404313 (phase 2, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: mk0633, comparator: placebo
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Documented clinical history of symptoms of chronic asthma, including dyspnea,
             wheezing, chest tightness, cough, and/or sputum production

          -  Males and females 18-70 years of age

        Exclusion Criteria:

          -  History of kidney or chronic liver disease

          -  Recent history of heart problems within the past 3 months

          -  Evidence of another clinically significant, active lung disorder such as
             bronchiectasis or COPD
Clinical trial NCT01359943 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  presence of RA classified by ACR 2010 revised criteria for at least 3 months before
             screening

          -  must have been taking MTX for at least 3 months before randomization and must
             currently be on a stable dose of MTX for at least 4 weeks before randomization.

          -  At Baseline: Disease activity criteria defined by >6 tender joints out of 68 and >6
             swollen joints out of 66 and with at least 1 of the following at screening: Anti-CCP
             antibodies positive OR Rheumatoid Factor positive and with at least 1 of the following
             at screening: hsCRP ≥ 10 mg/L OR ESR ≥ 28

        Exclusion criteria:

          -  RA patients functional status class IV according to the ACR 1991 revised criteria

          -  Previous exposure to secukinumab or any other biologic drug directly targeting IL-17
             or IL-17 receptor

          -  Previous exposure ever to an anti-TNF-a agent or any other immunomodulatory biologic
             agent (experimental or approved)

          -  Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or
             morphine)

          -  Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronan) required
             for treatment of arthritis within 4 weeks before randomization

          -  Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00309881 (phase 2, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of previously treated chronic lymphocytic leukemia (CLL) meeting
             the following criteria:

               -  Binet stage B (Rai stages I and II) or Binet stage C (Rai stages III and IV)
                  disease

               -  Rapid disease progression, symptomatic enlarged lymph nodes, or severe B-cell
                  symptoms

          -  CLL with autoimmune hemolytic anemia allowed

          -  Richter transformation allowed

        PATIENT CHARACTERISTICS:

          -  Life expectancy > 3 months

          -  ECOG performance status 0-3

          -  No severe organ dysfunction

          -  No other prior or concurrent neoplasms

        PRIOR CONCURRENT THERAPY:

          -  No more than 4 prior chemotherapy regimens